Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23883078 | 1.00 | CYP2D6 (0.47) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL1477176 | 1.00 | CYP2D6 (0.47) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL1893070 | 1.00 | CYP2D6 (0.47) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL27562832 | 0.83 | CYP2D6 (0.54) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL17135015 | 0.81 | CYP2D6 (0.53) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| Adamantane SCHEMBL15865265 | 0.81 | CYP2D6 (0.51) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| Hydroxyamine SCHEMBL599912 | 0.80 | ALDH1A1 (0.58) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| Fluoromethane SCHEMBL20577007 | 0.80 | GAA (0.56) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| Hydrazine SCHEMBL8861759 | 0.80 | ALDH1A1 (0.58) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| Methylamine SCHEMBL4135110 | 0.80 | ALDH1A1 (0.58) | CYP2D6ALDH1A1LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| CN-119585250-A | KIT inhibitors | 蓝图药品公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2023169336-A1 | PYRIDAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 成都科岭源医药技术有限公司 | 2023-09-14 | — | — | WO | disclosed |
| CN-108329311-B | Tricyclic compound as selective estrogen receptor down-regulator and application thereof | 南京圣和药业股份有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-0743299-B1 | Process for the preparation of 2-fluorocyclopropylamine sulfonic acid salts | BAYER AG (DE) | 1999-09-15 | — | — | EP | disclosed |
| EP-0743299-A1 | Process for the preparation of 2-fluorocyclopropylamine sulfonic acid salts and the chemical compound 2-fluorocyclopropylisocyanate | BAYER AG (DE) | 1996-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270190-A1 | KIT INHIBITORS | KIT, ABL1, APC | CYP2D6 4263/4885ALDH1A1 1119/4885LMNA 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.